261 records found.
Feb 27, 2020
Global Lung Cancer Therapeutics Market: Growth, Trends & Forecasts (2020-2025)
Feb 27, 2020
Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Feb 19, 2020
Nimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
Feb 19, 2020
Big Advances in Breast Cancer Screening Creating Sizable Opportunities
Feb 18, 2020
The First Patient Included in Japan in Isofol's Phase 3 AGENT Study
Feb 11, 2020
Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech's Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup
Feb 10, 2020
Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors
Jan 22, 2020
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Jan 14, 2020
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Jan 09, 2020
Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Jan 08, 2020
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 08, 2020
BioLineRx to Present at the 2020 Biotech Showcase
Dec 24, 2019
The global colorectal cancer market is expected to reach US$ 22,953.8 Mn in 2027 from US$ 16,339.9 Mn in 2018
Dec 20, 2019
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Dec 13, 2019
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Dec 11, 2019
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
Dec 08, 2019
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 06, 2019
Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

Pages